←
A-Alpha Bio112 posts
A-Alpha Bio avatar

A-Alpha Bio

@AAlphaBio

Transforming drug development by rapidly and quantitatively measuring the affinities of millions of protein-protein interactions - we're hiring!

◷ Joined April 2018▧ 27 Photos and videos
A-Alpha Bio avatar
A-Alpha Bio@AAlphaBio·13 Nov 2024

Check out our new AlphaBind preprint demonstrating our industry-leading antibody optimization model! Also excited to share that we have measured our BILLIONTH protein-protein interaction, providing the crucial training data to predict protein binding. biorxiv.org/content/10.1101/…

David Younger avatar
⟳ A-Alpha Bio retweeted
David Younger@DavidAYounger·7 Dec 2023

Excited to share our new paper using AlphaSeq data to enable predictive ML models for antibody engineering with our wonderful collaborators at @Google and @LumenBio biorxiv.org/content/10.1101/…

Madrona avatar
⟳ A-Alpha Bio retweeted
Madrona@MadronaVentures·11 Jan 2023

Don't miss our first Founded & Funded of the year! @CPicardo talks w/ @AAlphabio's @DavidAYounger about #ML in #biotech, building business models around data, and when the CEO shouldn't be in the room! Full episode 👉 https://t.co/IlHmTQKTwb What advice do you have for founders?

1:00
David Younger avatar
⟳ A-Alpha Bio retweeted
David Younger@DavidAYounger·5 Jan 2023

It was a pleasure speaking with @CPicardo from @MadronaVentures about @AAlphaBio and building a company at the intersection of life science and data science. Thank you for featuring A-Alpha Bio in the first Founded and Funded podcast of 2023!

This week on Founded & Funded, @CPicardo is talking with @DavidAYounger from @AAlphaBio — the first biotech company to make the #IA40. They dive into #ML in #biotech, building cross-functional teams & having both tech and biotech-focused investors. 👂 👉 https://t.co/IlHmTQKTwb

View quoted post ↗
Madrona avatar
⟳ A-Alpha Bio retweeted
Madrona@MadronaVentures·15 Dec 2022

Applied machine/deep learning & #lifesciences are coming together to transform how we understand & improve life/health. We want to partner w/ teams focused on building wet/dry lab platforms & novel datasets to disrupt traditional drug discovery processes. https://t.co/NuZUBgk1rs

Genome Startup Day avatar
⟳ A-Alpha Bio retweeted
Genome Startup Day@GenomeStartup·31 Mar 2022

A special thank you to our alumni sponsors who participated in previous Genome Startup Day discussions & continue to support our events. We appreciate your contributions to making this an impactful and collaborative community. @TwinStrandBio, @AAlphaBio, @WatchmakerGeno @seqWell

Post attachment
A-Alpha Bio avatar
A-Alpha Bio@AAlphaBio·29 Mar 2022

A-Alpha Bio has been selected as a finalist for the annual @geekwire Awards Health Innovation of the Year! It's a fantastic honor to be recognized as a finalist and a testament to the incredible science A-Alpha Bio is doing and our company's progress. geekwire.com/2022/announcing…

A-Alpha Bio avatar
A-Alpha Bio@AAlphaBio·27 Jan 2022

As we prepare for a virtual company-wide retreat tomorrow, we can't help but reminisce on previous in-person team events and how much fun they were...looking forward to the return of more moments like these soon!

Post attachmentPost attachmentPost attachmentPost attachment
A-Alpha Bio avatar
A-Alpha Bio@AAlphaBio·22 Dec 2021

"The partnership is the first announced by A-Alpha Bio in the cutting-edge and rapidly growing area of targeted protein degradation and leverages the AlphaSeq platform to quantitatively measure protein-protein binding..." Read more below in case you missed our exciting news!

SynBioBeta@SynBioBeta20 Dec 2021

.@AAlphaBio Partners with @KymeraTx to Discover Novel Interactions for Molecular Glue Discovery ow.ly/2NzG50HeJBX

View quoted post ↗
Kymera Therapeutics avatar
⟳ A-Alpha Bio retweeted
Kymera Therapeutics@KymeraTx·16 Dec 2021

@KymeraTx is thrilled to partner with @AAlphaBio to discover and characterize novel pairs of E3 ubiquitin ligases and high-value therapeutic targets for the rational and prospective design and development of molecular glues.

We're delighted to share that we have partnered with @KymeraTx to take on the field of targeted protein degradation! Using our AlphaSeq assay, we'll identify novel interactions between high value undruggable targets and a library of E3 ubiquitin ligases to discover mol glues(1/3)

View quoted post ↗